While the bank raised its price target on the stock to $490 from $400, analysts caution that “execution risk is high and TSLA is trading at a level that captures much of our base case long-term ...
Moderna ( MRNA) was the best-performing stock in the S&P 500 on expectations the vaccine maker’s experimental shot against bird flu will be in demand after the U.S. reported the first human death from ...